Intas Biopharmaceuticals Limited (IBPL) has fully integrated biopharmaceutical operations at Ahmedabad, Gujarat. Since the launch of biotechnology operations in May 2000, Research & Development (R&D) and manufacturing of biopharmaceutical products with a special focus on Oncology (Cancer) are major thrust areas for the company. Being India’s first and only biopharmaceuticals company to receive EUROPEAN UNION – GOOD MANUFACTURING PRACTICE (EU-GMP) certification for its manufacturing facility, IBPL has carved a niche in the biopharmaceutical operations In terms of quality standards, the facility complies with strict international Good Manufacturing Practice regulations and conforms to guidelines laid down by WORLD HEALTH ORGANIZATION (WHO). Starting with bio-generics, IBPL has structured its progression to the development of proprietary and innovative recombinant biopharmaceuticals. The company has successfully launched bio-similar products ? NEUKINE (rHu G-CSF) ? ERYKINE & EPOFIT (rHu EPO) ? INTALFA (rHu IFN Alfa-2b) ? NEUPEG (Pegylated rHu G-CSF) It is the only company in the state of Gujarat with an impressive record of accomplishment of having a strong marketing network for indigenously developed biotechnology products of IBPL and oncology products, manufactured by Group Company of Intas. It has one the most comprehensive oncology product baskets catering to Solid Tumours, Haematological Malignancies and Supportive Therapies. IBPL’s indigenously developed biopharmaceutical products are currently under registration in more than 60 countries. The company has also entered into several supply and marketing agreements with reputed international companies in regulated and semi-regulated markets of Europe, Asia-Pacific, Middle East, Russia & CIS, South and Central America and Africa. Currently the company is executing Contract Research and Manufacturing Agreements for a European client for development, scale-up and commercial supply of a novel bio-therapeutic protein. Under Strategic Research initiative, company is focusing on developing Novel Drug Delivery System for proteins, a cloning facility, introducing novel production platforms, developing Monoclonal Antibodies and recombinant products (cytokines, hormones and blood factors) as well as to facilitate the company’s foray in the molecular diagnostic market. Some of the strategic research projects to develop novel formulations and production platforms have been funded by Department of Science and Technology and Department of Biotechnology, Government of India as a public-private initiative of the Government of India. Subsidiaries of IBPL: Indus Biotherapeutics is a dedicated biopharmaceutical Contract Research Organization. This company solely concentrates on research and development of novel targets as well as bio-generics. Indus’ expertise lies in process and product development, analytical method development, bio-chemical immunological analysis, process validation, scale-up and technology transfer to manufacturing scale. Celestial Biologicals, associate company of IBPL, focuses on manufacturing and marketing of plasma-derived products. The company has commenced marketing of plasma proteins – Albumin and Immunoglobulins (IVIG) – under the respective brand names of “Albucel” and “Globucel” in the Indian market, and has plans to expand its product portfolio. Celestial Biologicals is the only player in India, which sources plasma from various blood banks in India, and obtains fractionated plasma proteins through a contractual arrangement. It plans to invest heavily in creating South Asia’s largest plasma fractionation facility.